The RFI anatomy: six real Latin American regulator rejections, deconstructed

Direct answer: an RFI on translation grounds is a regulatory-integrity finding

A Request for Information (RFI) issued by a Latin American health authority on translation grounds is not a linguistic problem. It is a regulatory-integrity finding that stops the submission clock, resets the review timeline, and costs a sponsor an average of 14 to 42 calendar days per occurrence across the LATAM regulators Amavita Sciences serves.

Below we deconstruct six real translation-grounds RFIs — one each from INVIMA (Colombia), ANVISA (Brazil), COFEPRIS (Mexico), ANMAT (Argentina), ISP (Chile), and DIGEMID (Peru) — showing the exact clause the regulator flagged, the underlying linguistic error, which deterministic QC gate would have caught it, and the days of delay it produced.

Why translation-grounds RFIs are underdiscussed and undermeasured

Every major regulator publishes deficiency response mechanisms. ANVISA's RDC 945/2024 and IN 338/2024 formalize the exigência process. COFEPRIS provides a 30-to-45-day response window on identified deficiencies, and its DIGIPRiS platform allows one prevention and one response to prevention per submission. INVIMA operates under Decreto 4725 de 2005, which expressly authorizes technical or scientific information in English provided an official Spanish translation is included.

What none of these public documents tells you is what happens when the translation itself is the deficiency. Translation-grounds RFIs are recorded in regulator systems as generic "language" or "documentation" findings. They are not aggregated in a public database. There is no benchmark for translation-grounds RFI rate, and no industry taxonomy for the linguistic error classes that produce them.

We built one. Over the past 24 months, working across bioaccess CRO submissions and Amavita Sciences translation batches, we have catalogued more than 200 translation-grounds RFIs. The six cases below are representative — one per regulator, drawn from the six most common error classes we observed. Identifying details have been altered; the regulator clauses, response windows, and linguistic mechanics are preserved.

The seven-gate QC architecture referenced in this post

1. Structural inventory — every heading, section, table, figure, cross-reference, and embedded artifact accounted for between source and target.
2. Numeric integrity — every value, unit, decimal separator, and range compared byte-for-byte across source and target.
3. Unit consistency — SI conversions, unit strings, and locale-specific decimal punctuation normalized and verified.
4. Negation preservation — every negation, contraindication, and prohibition compared for polarity inversion.
5. Entity mapping — every proper noun, drug name, device name, active ingredient, and regulatory entity resolved against a maintained glossary.
6. Adversarial back-translation — a separate model translates the target back into source, and reconciliation flags anywhere the round-trip drifts.
7. Document Currency — every foreign-issued document (CPP, CLC, GMP certificate, ISO 13485 certificate, apostille or consular legalization) verified within its jurisdictional validity window at the moment of filing.

No Big Four language services provider publishes a QC architecture organized this way. The closest published system is RWS's six checkpoints across a four-phase process, which are organized by role and phase rather than by failure class. Amavita publishes seven gates organized by failure class, including Document Currency — a defect class the phase-organized approach cannot see.

Case 1 — INVIMA (Colombia): the missing section cross-reference

The RFI

INVIMA issued a requerimiento on a Class III cardiovascular device dossier submitted under Decreto 4725. The Spanish Instructions for Use referenced "Sección 6.3" in the contraindications block, but Sección 6.3 contained warnings, not contraindications. The English source correctly referenced Section 6.4. Somewhere in translation, 6.4 became 6.3.

The linguistic error

The Spanish target had been produced by a boutique provider using a translation memory that predated a source revision. English Section 6.3 had been split into 6.3 (warnings) and 6.4 (contraindications). The segment-level updates preserved the new content but not the cross-reference. The two-linguist QC reviewed prose fluency and terminology, not the structural cross-reference graph.

Which gate catches this

Gate 1, structural inventory. The gate compares the source document's cross-reference graph — every "see Section X.Y" pointer and the section it targets — against the target document's graph. Any orphaned pointer, mismatched target, or drifted numbering triggers a batch hold before release.

Days of delay

INVIMA's response window is 30 business days. The sponsor responded on day 18; the technical panel needed a further 14 business days to reprocess. Total added timeline: 32 business days, roughly seven calendar weeks from RFI issuance to closure.

Case 2 — ANVISA (Brazil): the missing Portuguese amendment

The RFI

ANVISA issued an exigência on a clinical trial dossier submitted under RDC 945/2024. Amendment 3 was submitted in English with a stated Portuguese translation attached — but the attached Portuguese file was Amendment 2. The English Amendment 3 introduced a new inclusion criterion that never appeared in Portuguese.

The linguistic error

A file-naming error during dossier assembly. The Portuguese Amendment 3 had been produced, QC'd, and delivered on time; the wrong file was linked from the submission tree. The translation was correct; the assembly was wrong. The vendor released the file without a version fingerprint the sponsor's assembly system could verify.

Which gate catches this

The cryptographic audit ledger, not one of the seven QC gates. Every released batch carries a SHA-256 fingerprint per document plus a batch-level Merkle root, so the assembly system can programmatically verify that the file it is about to submit matches what was released. Any post-release swap, rename, or misassembly triggers a mismatch.

Days of delay

The response window on an exigência is typically 30 calendar days. The sponsor responded on day 6 and ANVISA re-reviewed within 21 days: 27 calendar days added. Under RDC 945/2024, an unsatisfactory response means rejection and full resubmission — the outcome a slower sponsor would have faced.

Case 3 — COFEPRIS (Mexico): the silent locale conversion

The RFI

COFEPRIS issued a prevención on a Class II infusion pump submission. The Spanish IFU stated a flow rate of "999 ml/hr" while adjacent cells had been converted to Spanish decimal commas. The unit spelling was not the finding — the inconsistent locale formatting was. The reviewer inferred a possible source-document mismatch against the declared performance range of 0.1 mL/h to 999 mL/h.

The linguistic error

Partial locale conversion. The translator ran a find-and-replace converting decimal periods to commas and missed instances inside a numbered range. The vendor's QC performed terminology review but no locale-consistency pass across the document.

Which gate catches this

Gate 3, unit consistency. It performs a locale-consistency pass over the whole target, verifying decimal separator conventions, unit-string spellings, and range delimiters are internally consistent and appropriate to the target locale (es-MX, es-CO, pt-BR and the rest). Any partial conversion triggers a batch hold.

Days of delay

The prevención window under DIGIPRiS is typically 30 to 45 calendar days, with one prevention and one response opportunity per submission. The sponsor responded on day 22 and COFEPRIS re-reviewed within 28 days: 50 calendar days added — and the sponsor's single response opportunity was spent on a formatting error.

Case 4 — ANMAT (Argentina): the inverted contraindication

The RFI

ANMAT issued an observación on a Class III neurostimulation device submission. The Spanish IFU read "Este dispositivo puede utilizarse en pacientes con marcapasos cardíacos implantados." The English source read "This device may not be used in patients with implanted cardiac pacemakers." The negation had been dropped — a safety inversion, not a translation quibble. ANMAT placed a hold on the submission and required evidence of the translation QC process applied.

The linguistic error

Negation dropout. English "may not" requires the translator to recognize "not" as a scope-taking negator over the modal predicate. A certified perito with twelve years of medical translation experience dropped it, and a fluency-oriented second review did not perform a source-target polarity check on safety-relevant sentences.

Which gate catches this

Gate 4, negation preservation, parses every source sentence for negators, quantifiers, and modal operators and verifies the target preserves polarity. Gate 6, adversarial back-translation, is the failsafe: a negation inversion produces a maximum-severity drift signal on reconciliation. Two gates cover this class because the architecture assumes any single gate can fail.

Days of delay

Internal quality investigation (14 days), IFU reissue (7 days), corrective action plan (7 days), hold released at day 45. The commercial impact exceeded the timeline: disclosure to the notified body triggered a supplementary QMS audit under ISO 13485, costing an estimated USD 45,000 in consultant time and internal disruption.

Case 5 — ISP (Chile): the untranslated excipient list

The RFI

ISP flagged a combination-product submission whose Spanish IFU listed excipients in English: lactose monohydrate, microcrystalline cellulose, magnesium stearate, sodium starch glycolate. The reviewer required Spanish denominations and an affirmation that every technical term across the dossier had been reviewed for consistent translation, citing the Spanish-language and documentation requirements of Decreto Supremo 3 de 2010 — Artículo 74 item 5 (labeling and IFU in Spanish), Artículo 29 No. 10 (translation of foreign documents, signed off by a company officer), and Artículo 78 (consistency of product information across the dossier).

The linguistic error

Entity-mapping failure at the translation memory layer. An over-broad extraction rule treated any comma-separated list of nouns as a controlled-term list and protected the entire excipient roster from translation. QC did not review protected segments because protected segments are, by definition, not translation output.

Which gate catches this

• INN and generic names with official Spanish or Portuguese equivalents must be translated (lactose monohydrate → lactosa monohidrato).
• Brand names, protocol identifiers, and controlled trademarks must not be translated.
• Regulatory entities — agency names, statute citations — follow per-jurisdiction rules.

Gate 5, entity mapping, resolves every proper noun, drug name, device name, active ingredient, and excipient against a maintained per-locale glossary configured with the pharmacopeia terminology stack for each jurisdiction. Any protected segment containing an INN or generic term flags for review.

Days of delay

A 30-calendar-day response window; the sponsor responded on day 12 with a corrected IFU and a written quality attestation, and ISP re-reviewed within 18 days. Total added timeline: 30 calendar days.

Case 6 — DIGEMID (Peru): the missing rescue language

The RFI

DIGEMID issued an observación on a Class II diagnostic device submission. The Spanish IFU translated "If symptoms persist, consult a physician" literally. Peruvian regulation requires warning language in patient-facing IFUs for home-use diagnostics to include an explicit rescue instruction — a specific action, not a general referral. The reviewer required text specifying a 48-hour threshold, discontinuation of use, and referral to the nearest emergency service.

The linguistic error

Not a linguistic error in the conventional sense. It is a regulatory-adaptation failure: the target document was linguistically accurate and regulatorily unfit for the target jurisdiction.

Which gate catches this

None of the six. Amavita addresses it through jurisdiction-scoped regulatory-adaptation rulesets injected into the translation prompt at ingest, not after review — Peruvian rescue-instruction requirements for home-use diagnostics, Argentine informed-consent reading-level and reference-clause requirements, Brazilian labeling symbol-conformity requirements.

Days of delay

A 20-business-day response window; the sponsor responded on day 12 and DIGEMID re-reviewed within 15 business days. Total added timeline: 27 business days, roughly five and a half weeks.

Cross-case pattern: the seven RFI classes and the seven gates

Average timeline impact across the six cases is roughly 35 calendar days per RFI. When a submission carries multiple RFIs the impact stacks, because LATAM regulators run responses serially, not in parallel.

• First-patient-in delay on trials awaiting clinical trial authorization.
• Market-access delay on commercial registrations.
• Notified-body follow-up on findings that trigger QMS review.
• Consumption of finite response opportunities — DIGIPRiS allows one prevención response per submission.
• Sponsor-side disruption: internal quality investigations, corrective action plans, potential CAPA opening.

At an average clinical trial cost of USD 30,000 to 50,000 per day of delay for a Phase II or Phase III program, the direct cost of one translation-grounds RFI ranges from roughly USD 800,000 to USD 2.1 million.

What no Big Four provider publishes about this problem

• No Big Four provider names a single LATAM regulator on its regulatory landing page, with one exception: a single ANVISA case study.
• No Big Four provider publishes a per-error-class QC gate architecture; published systems are organized by phase and role.
• No Big Four provider publishes a cryptographic delivery artifact. The audit story is ISO certification plus, at best, signed certificates of translation — none of which gives file-level tamper-evident integrity a sponsor can verify programmatically.
• No Big Four provider publishes a cash-denominated first-pass acceptance guarantee. Commitments are process-based.

The Big Four are not bad vendors. They are enterprise providers whose value proposition is global scale plus certification, not LATAM regulatory-integrity engineering. The gap is architectural, not effort-based.

The seventh gate — Document Currency

In 2026 we added a seventh gate to close a defect class the original six could not see. Document Currency verifies that every foreign-issued document in a dossier — CPP, CLC, GMP certificate, ISO 13485 certificate, FDA documentation, apostille or consular legalization — sits within its own jurisdictional validity window at the moment of filing.

The gate was motivated by two calendar-driven regulator rules that fail perfectly translated dossiers:

• DIGEMID (Peru) — DS 016-2011-SA Art. 28: foreign documents older than two years are invalid regardless of translation quality.
• INVIMA (Colombia) — Decreto 677 de 1995: pharmaceutical Certificates of Pharmaceutical Product must be less than one year old at filing.

A dossier can pass all six linguistic gates and still fail on calendar. That is what the seventh gate now catches.

Five questions to ask your current translation vendor today

1. Do you publish a QC architecture organized by linguistic failure class, or by translator role?
2. Do you release each batch with a cryptographic fingerprint our assembly system can verify? If the answer is "we have ISO 27001," the answer is no.
3. Do you configure jurisdiction-specific regulatory-adaptation rules at ingest, or is adaptation the sponsor's responsibility post-translation?
4. What is your published response commitment if your translation causes an RFI? Amavita's First-Pass Acceptance Program pays USD 2,500 per business-day delay credit on Tier 1-A batches rejected on translation grounds, with a 48-hour re-issue SLA.
5. How many LATAM regulators do you name on your public marketing pages? If the number is zero, LATAM is not their category.

Case studies here are drawn from bioaccess CRO and Amavita Sciences platform data from 2024 to 2026, with identifying details altered. Regulator finding language is preserved in the original Spanish or Portuguese where quoted.

Frequently asked questions

What is a translation-grounds RFI?

A Request for Information issued by a health regulatory authority whose root cause is a linguistic or translation-adjacent deficiency in the submitted dossier — as distinct from a scientific, clinical, or manufacturing deficiency. Translation-grounds RFIs include cross-reference drift, version misalignment, locale-conversion errors, negation inversion, terminology or entity-mapping errors, and jurisdictional-adaptation failures.

How many days does a translation-grounds RFI add to a LATAM submission timeline?

Based on the six cases deconstructed in this post, the average impact is approximately 35 calendar days per RFI. The distribution runs from about 27 to about 50 calendar days depending on the regulator's response window, the sponsor's turnaround, and the finding class. Notified-body follow-up on Class IV safety findings can add additional weeks or months and unbudgeted audit cost.

Which LATAM regulator issues the most translation-grounds RFIs?

We do not publish a per-regulator RFI-rate benchmark because no such benchmark exists in public data. Based on a 24-month internal dataset across bioaccess CRO submissions, the highest translation-grounds RFI rates we observe are at COFEPRIS (Mexico) and ANVISA (Brazil) — a function of submission volume, technical review depth, and the regulators' response-opportunity structure rather than translation quality per se.

What is the difference between a translation error and a regulatory-adaptation error?

A translation error is a linguistic inaccuracy — a wrong word, a missing sentence, a misconverted number. A regulatory-adaptation error is a case where the translation is linguistically accurate but does not conform to the target jurisdiction's regulatory expectations, such as missing rescue language in a patient-facing warning. Language services providers are expected to prevent translation errors; very few are configured to prevent regulatory-adaptation errors, which require per-jurisdiction rulesets applied at ingest.

Does Amavita Sciences guarantee no RFIs will be issued on translated content?

The First-Pass Acceptance Program applies to Tier 1-A batches and pays USD 2,500 per business-day delay credit for RFIs issued on translation grounds, with a 48-hour re-issue SLA. The commitment is contractual and cash-denominated, not process-based. No vendor guarantees zero RFIs on any submission, because sponsor-side errors, source-document defects, and reviewer discretion remain out of scope. What Amavita commits to is financial risk transfer on the translation layer specifically.

What should sponsors ask their current translation vendor?

Whether the vendor publishes a QC architecture organized by linguistic failure class rather than translator role; whether each batch is released with a cryptographic fingerprint the sponsor's assembly system can verify; whether jurisdiction-specific regulatory-adaptation rules are configured at ingest; what the vendor's published response commitment is when its translation causes an RFI; and how many LATAM regulators the vendor names on its public pages.

Related reading

• The three bands of LATAM regulatory translation — how the freelance floor, the infrastructure band, and the Big Four ceiling price out.
• Regulatory translation is not a translation project — the infrastructure argument behind the seven-gate architecture.
• Translation QC for regulatory dossiers — the workflow that produces an auditable quality record.
• The LATAM regulatory translation matrix — tiering and language requirements per regulator.
• The costliest translation mistakes in regulatory filings — the error classes that trigger RFIs and how to catch them.
• Which regulators accept English dossiers — the country-by-country submission-language map.

Related articles

• QualityLATAMComplianceINFLESZ Threshold: Why 98% of Spanish ICFs FailThe Spanish-specific readability index LATAM IRBs increasingly enforce — and why 98.3% of Spanish ICFs already fail it.August 21, 2026 · 13 min read
• LATAMCompliancePreclinical Translation Across 19 LATAM CountriesWhat LATAM regulators and ethics committees actually require translated for the preclinical annex of clinical trial filings — 19 countries, 5 exceptions named.August 25, 2026 · 10 min read
• LATAMComplianceSworn vs. Certified Translation: When Each AppliesA document-by-document, country-by-country read on when LATAM and global regulators require a sworn public translator, when a certified statement is enough, and when neither is required at all.August 21, 2026 · 11 min read